Therapies inhibiting CD47-SIRPα interaction are expected to work in two ways: firstly, by activation of adaptive immunity, resulting in cytotoxic anti-tumor responses, and secondly, by activation of innate immunity, therefore promoting cancer cells destruction by macrophages [103]. The gene discussed is CD47; the disease is cancer.